A new positron emission tomography (PET) radiotracer can detect abdominal aortic (AAA) aneurysms and potentially predict when they will rupture, according to research presented at the annual meeting of the Society for Nuclear Medicine and Molecular Imaging 2021. With the goal of a new biometric marker associated with AAA, the radiotracer is effective in both diagnosis and information provision to aid in the development of treatments with AAA, none of which currently exist.
AAA is a life-threatening degenerative vascular disease. Occurs when blood vessels weakens and a lump forms in the abdominal aorta (the vessel that supplies blood flow to the abdominal organs and legs). AAAs usually remain asymptomatic until they show up breakage, which entails high mortality and a substantial burden on the healthcare system.
“At this time, the clinical diagnosis of AAA is based on anatomical measurements of AAA diameter, which is a poor marker for predicting rupture,” noted Gyu Seong Heo, Ph.D., researcher postdoctoral fellowship at the University of Washington School of Medicine in St. Louis. Louis, Missouri. “Therefore, there is an unmet clinical need for a new molecular biomarker to determine the underlying processes that lead to the expansion and rupture of the aneurysm and that serve as a therapeutic target for better treatment of patients with AAA “.
To explore this clinical need, the researchers identified the type 2 chemokine receptor (CCR2) as a potential and novel biomarker for the evaluation of AAA. They developed the new PET tracer, 64Cu-DOTA-ECL1i, and it has been used to make images of first patients with AAA. PET 64Cu-DOTA-ECL1i was confirmed to be safe and effective for CCR2 imaging in patients with AAA.
64Cu-DOTA-ECL1i was also used to evaluate CCR2-targeted treatment in preclinical AAA animal rupture models. In the models, the 64Cu-DOTA-ECL1i image was highly suggestive of subsequent AAA rupture. In addition, in a designated cohort of animals that received a CCR2 inhibitor as a form of therapy, researchers were able to demonstrate effective prevention of AAA rupture.
“Given the availability of CCR2 inhibitors for human use, our work has great potential to assess AAA vulnerability, examine AAA patients for CCR2-targeted treatment, and determine response to treatment for optimal outcome.” , said Heo.
Abstract 133. “Evaluation of CCR2 as a teranostic biomarker for abdominal aortic aneurysm”
Provided by the Society of Nuclear Medicine and Molecular Imaging
Citation: New Radiotracer Shows Promise to Predict Abdominal Aortic Aneurysm Rupture (2021, June 16) Retrieved June 16, 2021 from https://medicalxpress.com/news/2021-06-radiotracer -abdominal-aortic-aneurysm-rupture.html
This document is subject to copyright. Apart from any fair treatment for private study or research purposes, no part may be reproduced without written permission. Content is provided for informational purposes only.